Claim · 2025-06-03 · publication · Stated in source · Supported

Xu et al. (Nature Medicine, published online 3 June 2025) state that AI-discovered drugs have experienced similar levels of phase 2 failure as non-AI-discovered drugs, and that none has so far progressed through phase 3.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial → bears on → AI-discovered drug candidates succeed in clinical trials more often than historical averages

Where it appears

AI in science →

Claim and evidence

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trialbears on ↓AI-discovered drug candidates succeed in clinical trials more often than historical averages

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2025-06-03 · publication Records dated 2025 →
Role: Context
Register (kind of text): Nonfiction
Missing element: Addresses phases 2 and 3 only; it neither states nor disputes a higher success rate in phase I.

Scope and limitsThe record documents what this text states, in its register; it is not evidence that the proposition is true and implies no influence on or from any other text. The introduction of a sponsor-authored trial report, citing other literature (its references 20 and 21, not retrieved) for these statements.

The evidence 01

primary sourceSupports the claim

A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Nature Medicine · 2025-06-03

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“AI-discovered drugs have experienced similar levels of phase 2 trial failure as non-AI-discovered drugs20,21, and none has so far progressed through phase 3 trials21.”

Location in source Introduction

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Zuojun Xu; Feng Ren; Ping Wang; Alex Zhavoronkov
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ef9e787bc19076ee7fd0031e2edef34ff77b1f3796db7d7baa0e1ecefee66806). Nature Medicine article page, open access, version of record of 3 June 2025, as served on 2026-10-30. The author list is partial: it gives the authors the retrieved expression names and leaves out those it abbreviates.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Zuojun Xu, Feng Ren, Ping Wang, Alex Zhavoronkov, “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”, 2025-06-03.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (24 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. The authors' summary of the literature they cite. A cross-family machine check (2026-10-30, item B117) re-read the record’s sources and found full support. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. A passage of the document bears on the proposition without meeting its criterion; the record names the missing element. It is not an articulation and implies no influence.

Date. Online publication date printed on the article page.

Record ID aib-arg-p6-xu-2025